PSPA
MCID: PTT048
MIFTS: 64

Pituitary Adenoma, Prolactin-Secreting (PSPA)

Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Pituitary Adenoma, Prolactin-Secreting

MalaCards integrated aliases for Pituitary Adenoma, Prolactin-Secreting:

Name: Pituitary Adenoma, Prolactin-Secreting 58 12 13
Prolactinoma 12 54 60 76 56 45 15 74
Prolactin-Secreting Pituitary Adenoma 54 60 76
Prolactin-Producing Pituitary Gland Adenoma 54 17
Prl-Secreting Pituitary Adenoma 54 60
Pituitary Lactotrophic Adenoma 54 60
Lactotroph Adenoma 54 60
Prloma 54 60
Prolactinoma of Pituitary Gland 12
Prolactinoma, Familial 58
Familial Prolactinoma 12
Pspa 76

Characteristics:

Orphanet epidemiological data:

60
prolactinoma
Inheritance: Not applicable; Prevalence: 1-5/10000 (United Kingdom),6-9/10000 (Belgium),1-5/10000 (Switzerland),1-9/100000 (Malta); Age of onset: Adolescent,Adult,Childhood,Elderly; Age of death: normal life expectancy;

OMIM:

58
Inheritance:
familial tendency independent of association with men-1


Classifications:



Summaries for Pituitary Adenoma, Prolactin-Secreting

NIH Rare Diseases : 54 Prolactinoma is a tumor of the pituitary gland that causes increased levels of the hormoneprolactin. This hormone normally stimulates breast development and milk production in women. Prolactinoma can affect men or women. In women, the symptoms may include unusual milk production (galactorrhea) when not pregnant or nursing and having no menstrual cycles (amenorrhea). In men, the most common symptoms are decreased sex drive and infertility. Most prolactinomas occur by chance (sporadically) in people with no family history. In a small number of cases, prolactinoma may be caused by a genetic condition such as multiple endocrine neoplasia type 1 (MEN1) or familial isolated pituitary adenoma. Treatment for prolactinoma usually involves taking oral medications known as dopamine agonists. These medications can reduce prolactin levels and shrink the tumor. In more severe cases, radiation therapy or surgery may be needed.

MalaCards based summary : Pituitary Adenoma, Prolactin-Secreting, also known as prolactinoma, is related to prolactin producing pituitary tumor and hyperprolactinemia. An important gene associated with Pituitary Adenoma, Prolactin-Secreting is AIP (Aryl Hydrocarbon Receptor Interacting Protein), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Dopamine and Risperidone have been mentioned in the context of this disorder. Affiliated tissues include pituitary, thyroid and t cells, and related phenotypes are hypogonadotrophic hypogonadism and male hypogonadism

OMIM : 58 Prolactin-secreting pituitary adenoma, or prolactinoma, is the most common type of hormonally active pituitary adenoma. These tumors can also be seen as a feature of multiple endocrine neoplasia type I (MEN1; 131100). See also 102200 for a discussion of familial isolated pituitary adenoma (FIPA) and acromegaly due to a growth hormone (GH; 139250)-secreting pituitary adenoma, which are also caused by mutation in the AIP gene. Schlechte (2003) discussed prolactinoma in general terms as a clinical, diagnostic, and therapeutic problem. (600634)

UniProtKB/Swiss-Prot : 76 Prolactin-secreting pituitary adenoma: Most common type of hormonally active pituitary adenoma.

Related Diseases for Pituitary Adenoma, Prolactin-Secreting

Diseases related to Pituitary Adenoma, Prolactin-Secreting via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 229)
# Related Disease Score Top Affiliating Genes
1 prolactin producing pituitary tumor 32.2 DRD2 PRL SST
2 hyperprolactinemia 31.9 DRD2 GH1 IGF1 POMC PRL SST
3 pituitary adenoma 1, multiple types 31.7 AIP GH1 IGF1 PRL SST
4 pituitary apoplexy 30.9 AIP POMC PRL
5 gigantism 30.6 AIP GH1 PRL
6 pituitary carcinoma 30.4 POMC PRL SST
7 galactorrhea 30.3 DRD2 IGF1 PRL
8 multiple endocrine neoplasia, type i 30.3 GNAS MEN1 PRKAR1A PRL SST
9 amenorrhea 30.2 POMC PRL TRH
10 insulin-like growth factor i 30.1 GH1 IGF1 PRL SST
11 meningioma, familial 30.1 MEN1 SST SSTR2
12 lymphocytic hypophysitis 30.0 GH1 POMC
13 carcinoid syndrome 30.0 IGF1 MEN1 SST
14 craniopharyngioma 29.9 GH1 IGF1 PRL TRH
15 hypopituitarism 29.9 GH1 IGF1 POMC PRL
16 empty sella syndrome 29.9 GH1 IGF1 POMC PRL TRH
17 primary hyperparathyroidism 29.8 MEN1 PRKAR1A PRL
18 growth hormone deficiency 29.8 GH1 GHSR IGF1
19 adenoma 29.8 AIP GH1 GNAS IGF1 MEN1 POMC
20 mccune-albright syndrome 29.4 GH1 GNAS IGF1 PRL SST
21 fibrous dysplasia 29.4 GH1 GNAS IGF1 PRL SST
22 hypothyroidism 29.2 GH1 GNAS IGF1 POMC PRL TRH
23 pituitary tumors 29.1 AIP GH1 GNAS IGF1 MEN1 POMC
24 acromegaly 28.9 AIP GH1 GNAS IGF1 MEN1 POMC
25 silent pituitary adenoma 10.5 AIP MEN1
26 null pituitary adenoma 10.5 AIP MEN1
27 generalized resistance to thyroid hormone 10.4 PRL TRH
28 familial isolated pituitary adenoma 10.4 AIP CDH23
29 pituitary adenoma 10.4
30 bronchus adenoma 10.4 POMC SST
31 bronchial adenomas/carcinoids childhood 10.4 POMC SST
32 pancreatic somatostatinoma 10.4 MEN1 SST
33 fibrous dysplasia/mccune-albright syndrome 10.4 GH1 PRL
34 type c thymoma 10.4 SST SSTR2
35 intestinal neuroendocrine benign tumor 10.4 MEN1 SSTR1
36 small intestine neuroendocrine neoplasm 10.4 MEN1 SSTR1
37 schizophreniform disorder 10.4 DRD2 PRL
38 chiasmal syndrome 10.3 POMC PRL SST
39 nelson syndrome 10.3 POMC PRL SST
40 non-functioning pituitary adenoma 10.3 GH1 SST
41 carcinoid tumors, intestinal 10.3 MEN1 SST SSTR2
42 multiple endocrine neoplasia 10.3
43 serotonin syndrome 10.3 MEN1 SST SSTR1
44 hypothalamic disease 10.3 GH1 POMC PRL
45 acidophil adenoma 10.3 IGF1 POMC SST
46 sella turcica neoplasm 10.3 POMC PRL
47 sheehan syndrome 10.2 IGF1 POMC PRL
48 oncogenic osteomalacia 10.2 SSTR1 SSTR3 SSTR5
49 pituitary-dependent cushing's disease 10.2 POMC PRL SST TRH
50 suprasellar meningioma 10.2 POMC TRH

Graphical network of the top 20 diseases related to Pituitary Adenoma, Prolactin-Secreting:



Diseases related to Pituitary Adenoma, Prolactin-Secreting

Symptoms & Phenotypes for Pituitary Adenoma, Prolactin-Secreting

Human phenotypes related to Pituitary Adenoma, Prolactin-Secreting:

60 33 (show top 50) (show all 53)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hypogonadotrophic hypogonadism 60 33 hallmark (90%) Very frequent (99-80%) HP:0000044
2 male hypogonadism 60 33 hallmark (90%) Very frequent (99-80%) HP:0000026
3 impotence 60 33 hallmark (90%) Very frequent (99-80%) HP:0000802
4 galactorrhea 60 33 hallmark (90%) Very frequent (99-80%) HP:0100829
5 decreased fertility in females 60 33 hallmark (90%) Very frequent (99-80%) HP:0000868
6 decreased fertility in males 60 33 hallmark (90%) Very frequent (99-80%) HP:0012041
7 female hypogonadism 60 33 hallmark (90%) Very frequent (99-80%) HP:0000134
8 amenorrhea 60 33 hallmark (90%) Very frequent (99-80%) HP:0000141
9 decreased female libido 60 33 hallmark (90%) Very frequent (99-80%) HP:0030018
10 osteopenia 60 33 frequent (33%) Frequent (79-30%) HP:0000938
11 hypotension 60 33 frequent (33%) Frequent (79-30%) HP:0002615
12 vomiting 60 33 frequent (33%) Frequent (79-30%) HP:0002013
13 fatigue 60 33 frequent (33%) Frequent (79-30%) HP:0012378
14 osteoporosis 60 33 frequent (33%) Frequent (79-30%) HP:0000939
15 pallor 60 33 frequent (33%) Frequent (79-30%) HP:0000980
16 progressive visual loss 60 33 frequent (33%) Frequent (79-30%) HP:0000529
17 easy fatigability 60 33 frequent (33%) Frequent (79-30%) HP:0003388
18 headache 60 33 frequent (33%) Frequent (79-30%) HP:0002315
19 gynecomastia 60 33 frequent (33%) Frequent (79-30%) HP:0000771
20 dyspareunia 60 33 frequent (33%) Frequent (79-30%) HP:0030016
21 secondary growth hormone deficiency 60 33 frequent (33%) Frequent (79-30%) HP:0008240
22 pituitary hypothyroidism 60 33 frequent (33%) Frequent (79-30%) HP:0008245
23 adrenocorticotropin deficient adrenal insufficiency 60 33 frequent (33%) Frequent (79-30%) HP:0011735
24 adrenocorticotropic hormone deficiency 60 33 frequent (33%) Frequent (79-30%) HP:0011748
25 decreased circulating acth level 60 33 frequent (33%) Frequent (79-30%) HP:0002920
26 abnormality of hair density 60 33 frequent (33%) Frequent (79-30%) HP:0011357
27 ptosis 60 33 occasional (7.5%) Occasional (29-5%) HP:0000508
28 diplopia 60 33 occasional (7.5%) Occasional (29-5%) HP:0000651
29 seizures 60 33 occasional (7.5%) Occasional (29-5%) HP:0001250
30 blindness 60 33 occasional (7.5%) Occasional (29-5%) HP:0000618
31 delayed puberty 60 33 occasional (7.5%) Occasional (29-5%) HP:0000823
32 vertigo 60 33 occasional (7.5%) Occasional (29-5%) HP:0002321
33 growth hormone excess 60 33 occasional (7.5%) Occasional (29-5%) HP:0000845
34 bitemporal hemianopia 60 33 occasional (7.5%) Occasional (29-5%) HP:0030521
35 oculomotor nerve palsy 60 33 occasional (7.5%) Occasional (29-5%) HP:0012246
36 cranial nerve vi palsy 60 33 occasional (7.5%) Occasional (29-5%) HP:0006897
37 sudden loss of visual acuity 60 33 occasional (7.5%) Occasional (29-5%) HP:0001117
38 fourth cranial nerve palsy 60 33 occasional (7.5%) Occasional (29-5%) HP:0007011
39 internal ophthalmoplegia 60 33 occasional (7.5%) Occasional (29-5%) HP:0007942
40 nausea and vomiting 60 Frequent (79-30%)
41 cranial nerve paralysis 60 Occasional (29-5%)
42 anterior hypopituitarism 60 Occasional (29-5%)
43 hemianopsia 60 Occasional (29-5%)
44 hypogonadism 60 Very frequent (99-80%)
45 pituitary prolactin cell adenoma 33 HP:0006767
46 abnormality of the menstrual cycle 60 Very frequent (99-80%)
47 erectile abnormalities 60 Very frequent (99-80%)
48 abnormality of the pituitary gland 60 Very frequent (99-80%)
49 low gonadotropins (secondary hypogonadism) 60 Very frequent (99-80%)
50 menstrual irregularities 60 Very frequent (99-80%)

Symptoms via clinical synopsis from OMIM:

58
Oncology:
prolactinoma
prolactin-secreting pituitary adenoma

Clinical features from OMIM:

600634

GenomeRNAi Phenotypes related to Pituitary Adenoma, Prolactin-Secreting according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 9.92 AIP CDH23 CORT DRD2 GH1 GHSR

MGI Mouse Phenotypes related to Pituitary Adenoma, Prolactin-Secreting:

47 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.32 AIP CDH23 CORT DRD2 GHSR GNAS
2 behavior/neurological MP:0005386 10.29 CDH23 CORT DRD2 GHSR GNAS POMC
3 growth/size/body region MP:0005378 10.25 AIP CDH23 CORT DRD2 GHSR GNAS
4 endocrine/exocrine gland MP:0005379 10.21 AIP CORT DRD2 GNAS IGF1 MEN1
5 digestive/alimentary MP:0005381 10 CDH23 DRD2 GHSR MEN1 PRKAR1A SST
6 adipose tissue MP:0005375 9.97 DRD2 GHSR GNAS IGF1 POMC PRKAR1A
7 integument MP:0010771 9.92 AIP DRD2 GNAS IGF1 POMC PRKAR1A
8 liver/biliary system MP:0005370 9.8 AIP DRD2 GNAS MEN1 POMC PRKAR1A
9 neoplasm MP:0002006 9.76 AIP DRD2 GNAS IGF1 MEN1 POMC
10 nervous system MP:0003631 9.7 CDH23 DRD2 GNAS IGF1 MEN1 POMC
11 no phenotypic analysis MP:0003012 9.23 DRD2 GHSR GNAS POMC SST SSTR3

Drugs & Therapeutics for Pituitary Adenoma, Prolactin-Secreting

Drugs for Pituitary Adenoma, Prolactin-Secreting (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 76)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 62-31-7, 51-61-6 681
2
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
3 Dopamine Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
4 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
5 Psychotropic Drugs Phase 4
6 Dopamine Antagonists Phase 4
7 Serotonin Antagonists Phase 4
8 Serotonin Agents Phase 4
9 Tranquilizing Agents Phase 4
10 Antipsychotic Agents Phase 4
11 Central Nervous System Depressants Phase 4
12
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
13
Cabergoline Approved Phase 2, Phase 3,Not Applicable 81409-90-7 54746
14
Pasireotide Approved Phase 2, Phase 3 396091-73-9 9941444
15
Somatostatin Approved, Investigational Phase 2, Phase 3 38916-34-6, 51110-01-1 53481605
16 Antiparkinson Agents Phase 2, Phase 3,Phase 1,Not Applicable
17 Dopamine agonists Phase 2, Phase 3,Phase 1,Not Applicable
18 Peripheral Nervous System Agents Phase 2, Phase 3,Phase 1,Not Applicable
19 Autonomic Agents Phase 2, Phase 3,Phase 1,Not Applicable
20 Hormones Phase 2, Phase 3,Phase 1,Not Applicable
21 Hormone Antagonists Phase 2, Phase 3,Phase 1
22 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3,Phase 1
23 Cardiotonic Agents Phase 2, Phase 3,Phase 1,Not Applicable
24 Protective Agents Phase 2, Phase 3,Phase 1,Not Applicable
25 Sympathomimetics Phase 2, Phase 3,Phase 1,Not Applicable
26
Sodium Citrate Approved, Investigational Phase 2 68-04-2
27
Ropinirole Approved, Investigational Phase 1, Phase 2 91374-20-8, 91374-21-9 5095 497540
28
Bromocriptine Approved, Investigational Phase 2,Not Applicable 25614-03-3 31101
29
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
30
Enclomiphene Investigational Phase 2 15690-57-0
31
Lapatinib Approved March 2007, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
32 Estrogen Receptor Antagonists Phase 2
33 Selective Estrogen Receptor Modulators Phase 2
34 Zuclomiphene Phase 2
35 Estrogens Phase 2
36 Citrate Phase 2
37 Estrogen Antagonists Phase 2
38 Fertility Agents Phase 2
39 Clomiphene Phase 2
40 Estrogen Receptor Modulators Phase 2
41 Protein Kinase Inhibitors Phase 2
42
Turmeric Approved, Experimental, Investigational Phase 1
43
Curcumin Approved, Experimental, Investigational Phase 1 458-37-7 969516
44
Dexamethasone Approved, Investigational, Vet_approved Phase 1 50-02-2 5743
45
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 1 1177-87-3
46 Analgesics Phase 1,Not Applicable
47 Anti-Inflammatory Agents Phase 1,Not Applicable
48 Turmeric extract Phase 1
49 Antirheumatic Agents Phase 1,Not Applicable
50 Analgesics, Non-Narcotic Phase 1,Not Applicable

Interventional clinical trials:

(show all 28)
# Name Status NCT ID Phase Drugs
1 A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children Completed NCT01050582 Phase 4 Risperidone;Other atypical antipsychotic drugs
2 Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas Completed NCT01620138 Phase 2, Phase 3 Pasireotide;cabergoline
3 Clomiphene in Males With Prolactinomas and Persistent Hypogonadism Completed NCT00697814 Phase 2 Clomiphene citrate
4 Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy Completed NCT00939523 Phase 2 Lapatinib
5 Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole Recruiting NCT03038308 Phase 1, Phase 2 Ropinirole
6 Bromocriptine Quick Release (BCQR) as Adjunct Therapy in Type 1 Diabetes Recruiting NCT02544321 Phase 2 Bromocriptine
7 Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin Terminated NCT00958841 Phase 2 pasireotide LAR
8 Temozolomide in Treating Patients With Invasive Pituitary Tumors Withdrawn NCT00601289 Phase 2 temozolomide
9 Turmeric Effect on Reduction of Serum Prolactin and Related Hormonal Change and Adenoma Size in Prolactinoma Patients Unknown status NCT01344291 Phase 1 Curcumin
10 Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia Terminated NCT01088763 Phase 1 gamma-secretase/Notch signalling pathway inhibitor RO4929097;dexamethasone
11 Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools Unknown status NCT01775332 Not Applicable
12 Efficacy of Rapid Escalation of Cabergoline in Comparison to Conventional Dosing in Prolactin Secreting Macroadenomas. Unknown status NCT01143584 Not Applicable Cabergoline;cabergoline
13 Prevalence of Pituitary Incidentaloma in Relatives of Patients With Pituitary Adenoma Unknown status NCT00598949
14 Cardiac Valve Complications in Prolactinomas Treated With Cabergoline Completed NCT00460616 Cabergoline
15 Insulin Resistance in Women With Prolactinoma Completed NCT00481299
16 Rhinological Outcomes in Endonasal Pituitary Surgery Completed NCT01504399
17 Study on Therapy of Non-invasive Prolactinoma Recruiting NCT03353025 Not Applicable dopamine agonist treatment
18 Dopamine Agonists Withdrawal Study of Invasive Prolactinomas Involving the Cavernous Sinus Recruiting NCT02536261
19 An Investigation of Pituitary Tumors and Related Hypothalmic Disorders Recruiting NCT00001595
20 Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA Recruiting NCT00461188
21 Seoul National University Pituitary Disease Cohort Study Recruiting NCT03474601
22 PITUItary Carcinoma or Aggressive Tumors REgistry -Lyon Recruiting NCT02854228
23 Overall and Disease Specific Survival in Patients With Confirmed MEN1 With or Without PNET (Pancreatic Neuroendocrine Tumors) Active, not recruiting NCT03043508
24 Long Term Outcome Study in Patients With Pituitary Disorders Active, not recruiting NCT03665064
25 Dopamine D2 Receptors(D2R) Imaging in Prolactinomas Not yet recruiting NCT03717454 Not Applicable Drug treatment
26 Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas Not yet recruiting NCT03400865 Not Applicable HCQ/CQ and CAB combined treatment
27 Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma Not yet recruiting NCT03457389 Not Applicable Cabergoline
28 Intraoperative Ultrasound in Patients Undergoing Transsphenoidal Surgery for Pituitary Adenoma Not yet recruiting NCT03284775 Not Applicable

Search NIH Clinical Center for Pituitary Adenoma, Prolactin-Secreting

Cochrane evidence based reviews: prolactinoma

Genetic Tests for Pituitary Adenoma, Prolactin-Secreting

Anatomical Context for Pituitary Adenoma, Prolactin-Secreting

MalaCards organs/tissues related to Pituitary Adenoma, Prolactin-Secreting:

42
Pituitary, Thyroid, T Cells, Bone, Brain, Heart, B Cells

Publications for Pituitary Adenoma, Prolactin-Secreting

Articles related to Pituitary Adenoma, Prolactin-Secreting:

(show top 50) (show all 732)
# Title Authors Year
1
Endonasal Chiasmapexy Using Autologous Cartilage/Bone for Empty Sella Syndrome After Cabergoline Therapy for Prolactinoma. ( 30315973 )
2019
2
Glioblastoma and prolactinoma: a rare simultaneous occurrence. ( 30788103 )
2019
3
Different cabergoline effect on metabolic and anthropometric parameters in female prolactinoma patients versus idiopathic hyperprolactinemia patients. ( 30806330 )
2019
4
Status epilepticus induced by treatment with dopamine agonist therapy for giant prolactinoma: a case report. ( 30660191 )
2019
5
Cabergoline treatment in prolactinoma: Amelioration in obstructive and central sleep apneas. ( 30147082 )
2019
6
Familial Cancer Clustering in Patients with Prolactinoma. ( 30196424 )
2019
7
Pasireotide: A potential therapeutic alternative for resistant prolactinoma. ( 30318256 )
2019
8
Direct Carotid Cavernous Fistula Due to Rupture of a Cavernous Carotid Aneurysm Embedded Within a Prolactinoma After Cabergoline Administration. ( 30465960 )
2019
9
Management of Dopamine Agonist-Resistant Prolactinoma. ( 30481756 )
2019
10
PGAM5-CypD pathway is involved in bromocriptine-induced RIP3/MLKL-dependent necroptosis of prolactinoma cells. ( 30611988 )
2019
11
Clinical characteristics and surgical outcome of prolactinoma in patients under 14 years old. ( 30732174 )
2019
12
Long-term therapeutic success with multimodal therapy in aggressive prolactinoma. ( 30797752 )
2019
13
Dopamine Agonist-Induced Impulse Control Disorders in Patients With Prolactinoma: A Cross-Sectional Multicenter Study. ( 30848825 )
2019
14
THE EFFECT OF RALOXIFENE ON SERUM PROLACTIN LEVEL IN PATIENTS WITH PROLACTINOMA. ( 30865525 )
2019
15
miR-93-5p targets Smad7 to regulate the transforming growth factor-β1/Smad3 pathway and mediate fibrosis in drug-resistant prolactinoma. ( 30946881 )
2019
16
SUCCESSFUL TREATMENT OF A PROLACTINOMA (CASE REPORT). ( 30958283 )
2019
17
MANAGEMENT AND OUTCOMES OF GIANT PROLACTINOMA: A SERIES OF 71 PATIENTS. ( 30995432 )
2019
18
Bromocriptine and cabergoline induce cell death in prolactinoma cells via the ERK/EGR1 and AKT/mTOR pathway respectively. ( 31000722 )
2019
19
Relation of RANKL and OPG Levels with Bone Resorption in Patients with Acromegaly and Prolactinoma. ( 29895074 )
2018
20
Prolactin-Secreting Lung Adenocarcinoma Metastatic to the Pituitary Mimicking a Prolactinoma: A Case Report. ( 30137505 )
2018
21
Nonalcoholic fatty liver disease with prolactin-secreting pituitary adenoma in an adolescent: A case report. ( 30335007 )
2018
22
Improvement in cognitive abilities following cabergoline treatment in patients with a prolactin-secreting pituitary adenoma. ( 29035904 )
2018
23
Pituitary atypical teratoid rhabdoid tumor in a patient with prolactinoma: A unique description. ( 29110337 )
2018
24
Ectopic Prolactinoma Presenting as Bacterial Meningitis: A Diagnostic Conundrum. ( 29378345 )
2018
25
Giant prolactinoma, germline BRCA1 mutation, and depression: a case report. ( 30518416 )
2018
26
Transnasal Transsphenoidal Elevation of Optic Chiasm in Secondary Empty Sella Syndrome Following Prolactinoma Treatment. ( 29421446 )
2018
27
Non-obstructive hydrocephalus in a giant hemorrhagic prolactinoma. ( 29480687 )
2018
28
Multiple endocrine neoplasia type 1 presenting with concurrent insulinoma and prolactinoma in early-adolescence. ( 30127804 )
2018
29
Pituitary Apoplexy during Treatment of Prolactinoma with Cabergoline. ( 29492132 )
2018
30
Beneficial Effects of High Doses of Cabergoline in the Treatment of Giant Prolactinoma Resistant to Dopamine Agonists: A Case Report with a 21-Year Follow-Up. ( 28954263 )
2018
31
Males with prolactinoma are at increased risk of incident cardiovascular disease. ( 29044586 )
2018
32
Sex differences in the pituitary TGFβ1 system: The role of TGFβ1 in prolactinoma development. ( 29074127 )
2018
33
Pediatric prolactinoma: initial presentation, treatment, and long-term prognosis. ( 29168011 )
2018
34
Prolactinoma through the female life cycle. ( 29177641 )
2018
35
P21Waf1/Cip1 and p27Kip1 are correlated with the development and invasion of prolactinoma. ( 29230669 )
2018
36
Broad clinical spectrum and diverse outcomes of prolactinoma with pediatric onset: medication-resistant and recurrent cases. ( 29279457 )
2018
37
Characteristics of pericytes in diethylstilbestrol (DES)-induced pituitary prolactinoma in rats. ( 29344720 )
2018
38
Multiple Eyelid Cysts (Apocrine and Eccrine Hidrocystomas, Trichilemmal Cyst, and Hybrid Cyst) in a Patient With a Prolactinoma. ( 29351118 )
2018
39
The prolactin-release inhibitor paeoniflorin suppresses proliferation and induces apoptosis in prolactinoma cells via the mitochondria-dependent pathway. ( 29388711 )
2018
40
Natural and molecular history of prolactinoma: insights from a Prlr-/- mouse model. ( 29464061 )
2018
41
Medical Management of a Prolactinoma in a 15-Year-Old Girl. ( 29685620 )
2018
42
The Balance of PI3K and ERK Signaling Is Dysregulated in Prolactinoma and Modulated by Dopamine. ( 29726995 )
2018
43
Long-term follow-up of female prolactinoma patients at child-bearing age after transsphenoidal surgery. ( 29934876 )
2018
44
Comparison of Male and Female Prolactinoma Patients Requiring Surgical Intervention. ( 30009121 )
2018
45
ALK7 expression in prolactinoma is associated with reduced prolactin and increased proliferation. ( 30012586 )
2018
46
18F-FDOPA Uptake Reflects the Efficacy of Dopamine Agonists Treatment in Pituitary Prolactinoma. ( 30052596 )
2018
47
Role of TGF-β1/Smad3-mediated fibrosis in drug resistance mechanism of prolactinoma. ( 30055965 )
2018
48
Estrogen receptor antagonist fulvestrant inhibits proliferation and promotes apoptosis of prolactinoma cells by regulating the IRE1/XBP1 signaling pathway. ( 30106152 )
2018
49
Beat the giant: case of a giant prolactinoma during pregnancy on cabergoline. ( 30159146 )
2018
50
Fulvestrant inhibits the glycolysis of prolactinoma GH3 cells by downregulating IRE1/XBP1 signaling pathway. ( 30178863 )
2018

Variations for Pituitary Adenoma, Prolactin-Secreting

ClinVar genetic disease variations for Pituitary Adenoma, Prolactin-Secreting:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 LRP2 NM_004525.3(LRP2): c.13753C> T (p.Arg4585Ter) single nucleotide variant Likely pathogenic rs202057289 GRCh37 Chromosome 2, 169985570: 169985570
2 LRP2 NM_004525.3(LRP2): c.13753C> T (p.Arg4585Ter) single nucleotide variant Likely pathogenic rs202057289 GRCh38 Chromosome 2, 169129060: 169129060

Cosmic variations for Pituitary Adenoma, Prolactin-Secreting:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM771 PIK3CA pituitary,NS,adenoma,PRL c.3073A>G p.T1025A 3:179234230-179234230 0
2 COSM760 PIK3CA pituitary,NS,adenoma,PRL c.1624G>A p.E542K 3:179218294-179218294 0
3 COSM483 HRAS pituitary,NS,adenoma,GH c.35G>T p.G12V 11:534288-534288 0
4 COSM482 HRAS pituitary,NS,adenoma,PRL c.34G>C p.G12R 11:534289-534289 0
5 COSM27887 GNAS pituitary,NS,adenoma,GH c.601C>T p.R201C 20:58909365-58909365 0
6 COSM27895 GNAS pituitary,NS,adenoma,GH c.602G>A p.R201H 20:58909366-58909366 0
7 COSM27899 GNAS pituitary,NS,adenoma,GH c.601C>A p.R201S 20:58909365-58909365 0
8 COSM27896 GNAS pituitary,NS,adenoma,GH c.680A>G p.Q227R 20:58909541-58909541 0
9 COSM27888 GNAS pituitary,NS,adenoma,GH c.680A>T p.Q227L 20:58909541-58909541 0

Expression for Pituitary Adenoma, Prolactin-Secreting

Search GEO for disease gene expression data for Pituitary Adenoma, Prolactin-Secreting.

Pathways for Pituitary Adenoma, Prolactin-Secreting

GO Terms for Pituitary Adenoma, Prolactin-Secreting

Cellular components related to Pituitary Adenoma, Prolactin-Secreting according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.5 DRD2 SSTR1 SSTR2 SSTR3 SSTR4 SSTR5
2 plasma membrane GO:0005886 9.44 AIP CDH23 DRD2 GHSR GNAS PRKAR1A
3 endosome lumen GO:0031904 9.26 GH1 PRL
4 secretory granule GO:0030141 9.16 POMC TRH

Biological processes related to Pituitary Adenoma, Prolactin-Secreting according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.87 POMC SST SSTR3 TRH
2 negative regulation of cell proliferation GO:0008285 9.86 DRD2 MEN1 SST SSTR1 SSTR2 SSTR3
3 forebrain development GO:0030900 9.8 DRD2 SSTR1 SSTR2 SSTR3 SSTR4
4 response to drug GO:0042493 9.79 DRD2 GNAS SST
5 female pregnancy GO:0007565 9.77 GHSR GNAS PRL
6 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.77 SSTR1 SSTR2 SSTR3 SSTR4 SSTR5
7 G protein-coupled receptor signaling pathway GO:0007186 9.77 CORT DRD2 GHSR GNAS POMC SST
8 cellular response to glucocorticoid stimulus GO:0071385 9.73 SSTR2 SSTR3 SSTR4 SSTR5
9 cerebellum development GO:0021549 9.72 SSTR1 SSTR2 SSTR3
10 cellular response to estradiol stimulus GO:0071392 9.7 SSTR1 SSTR2 SSTR3
11 positive regulation of multicellular organism growth GO:0040018 9.69 DRD2 GH1 GHSR
12 response to starvation GO:0042594 9.67 SSTR1 SSTR2 SSTR3
13 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.65 GH1 GHSR IGF1
14 neuropeptide signaling pathway GO:0007218 9.63 POMC SSTR1 SSTR2 SSTR3 SSTR4 SSTR5
15 response to ethanol GO:0045471 9.62 DRD2 TRH
16 response to estradiol GO:0032355 9.61 GH1 GHSR
17 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.59 GH1 PRL
18 positive regulation of growth GO:0045927 9.58 GH1 GHSR
19 peristalsis GO:0030432 9.58 DRD2 SSTR2
20 postsynaptic modulation of chemical synaptic transmission GO:0099170 9.56 DRD2 GHSR
21 hormone-mediated apoptotic signaling pathway GO:0008628 9.54 SST SSTR3
22 somatostatin signaling pathway GO:0038170 9.02 SSTR1 SSTR2 SSTR3 SSTR4 SSTR5
23 signal transduction GO:0007165 10.1 DRD2 GHSR GNAS IGF1 POMC SSTR1
24 regulation of signaling receptor activity GO:0010469 10 CORT GH1 IGF1 POMC PRL SST

Molecular functions related to Pituitary Adenoma, Prolactin-Secreting according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.87 DRD2 GHSR SSTR1 SSTR2 SSTR3 SSTR4
2 neuropeptide binding GO:0042923 9.55 SSTR1 SSTR2 SSTR3 SSTR4 SSTR5
3 G protein-coupled receptor binding GO:0001664 9.54 CORT GNAS POMC
4 hormone activity GO:0005179 9.5 CORT GH1 IGF1 POMC PRL SST
5 insulin-like growth factor receptor binding GO:0005159 9.4 GNAS IGF1
6 prolactin receptor binding GO:0005148 9.26 GH1 PRL
7 somatostatin receptor activity GO:0004994 9.02 SSTR1 SSTR2 SSTR3 SSTR4 SSTR5

Sources for Pituitary Adenoma, Prolactin-Secreting

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....